Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...